Total Funding
29
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
204094
NantKwest is a clinical-stage immunotherapy company focused on harnessing the immune system to treat disease.
Frances Toneguzzo: Executive Vice PresidentPast Role: Tufts University, Director, Office for Technology & Industry Collaboration- Barry Simon: President and COO
NantWorks
About the Company
NantKwest is a clinical-stage immunotherapy company focused on harnessing the immune system to treat disease. It is a biotechnology company, engages in developing immunotherapeutic agents for various clinical conditions in the United States. The company’s product candidates include activated natural killer candidates for the treatment of
virally-induced cancers, such as human papilloma virus-induced cervical, and head and neck cancers; ebola; and serious viral, fungal, and bacterial infections, as well as that is in Phase II clinical trials for the treatment of polyoma virus-induced merkel cell carcinoma.
